ELROMO 75MG

Elromo 75mg Tablet is an anticoagulant medication that belongs to the class of thrombopoietin (TPO) receptor agonists and contains the active ingredient Eltrombopag. It is primarily prescribed to treat low platelet counts caused by conditions such as primary immune thrombocytopenia (ITP), a disorder in which the body’s immune system attacks its own platelets, and hepatitis C virus (HCV) infection. In ITP, low platelet levels can lead to increased risks of bruising and severe bleeding. This medication is also used in adults with severe aplastic anaemia, a condition where the bone marrow fails to produce enough blood cells, resulting in low counts of red cells, white cells, and platelets.

Elromo works by stimulating the production of platelets, thereby reducing the risk of bleeding. However, it is important to avoid this medication in individuals who are allergic to Eltrombopag or any of its components. Allergic reactions may include symptoms like rash, itching, swelling, dizziness, or breathing difficulty. It is also contraindicated in patients with severe liver disease or impaired liver function, as it can cause further damage by increasing liver enzymes and bilirubin levels. Because of its potential impact on the eyes, doctors may recommend regular eye exams to monitor for cataracts and retinal issues, especially if you don’t already have routine eye checks.

The medication must be taken as prescribed, and the dose may be adjusted depending on your platelet count to prevent the levels from rising too high, which can increase the risk of blood clots. It is essential not to stop the medicine abruptly, as platelet levels may drop quickly, increasing the likelihood of bleeding. Additionally, patients should avoid consuming dairy products or calcium-rich foods and drinks close to the time of taking this tablet, as calcium can interfere with its absorption and reduce its effectiveness.

Women undergoing treatment with Elromo should use effective birth control and inform their doctor immediately if they become pregnant. This medication is not suitable for children under one year of age with ITP, nor is it recommended for individuals under 18 years old being treated for HCV-related low platelet counts or severe aplastic anaemia.

Before starting the medication, it is crucial to inform your doctor about all the medicines you are taking or have recently taken, including prescription and non-prescription drugs, vitamins, and herbal supplements, as some of these may interact with Elromo and cause undesirable effects